Ran Amir, Ran joins MigVax after three years as CEO of CannAssure Therapeutics (TASE: CSURE), a medical cannabis company which he led from the concept stage to 80 employees and tens of millions in revenues. Previously, he served for five years as General Manager of CHS Israel, the Israeli branch of the CHS Agribusiness Cooperative (Nasdaq: CHSCP), a Fortune 500 agricultural leader, and as CEO of Solbar Food Technologies. Ran holds a B.Sc. in Industrial Engineering and Management from the Shenkar School of Engineering, and an M.Sc. in International Business from the University of London.
David Zigdon, is a senior-level executive with a strong background in the High-Tech, Biomed, Biotech, and Pharma startup industry. coordinate this activity. Mr. Zigdon was CEO and President of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage BioMed startups. Rad BioMed is part of the RAD Group that been named "the most fertile ground" for developing Israeli entrepreneurs. Before that David had a two-decade career as CEO/CFO of successful high tech firms, including Bynet, Bynet Electronics, Radcom (Nasdaq: RDCM), Magic Software (Nasdaq: MGIC) and Time To Know.
Mr. Zigdon is a CPA and holds a BA degree (Economics) and an LLM degree from Bar Ilan University.
Prof. Itamar Shalit
Prof Itamar Shalit is an expert in infectious diseases, actively involved in various national committees of the Israeli Ministry of Health. He was awarded Certificate of Appreciation Declaration by the World Health Organization for his role in eradicating poliomyelitis in Israel. In the past, Prof Shalit also served as the Director General of Schneider Children’s Hospital and of Carmel Hospital, and was the Chairman of the Israeli Society for Infectious Diseases. Prof Shalit serves as a Member of the Scientific Advisory Board at BioLineRx, Ltd., NasVax, and Therapix Biosciences Ltd. Prof Shalit served as a Member of the Scientific Advisory Board at Teva Innovative Ventures until 2011. Currently, he serves as CEO of the Galilee Biomedical Research Administration. Prof Shalit holds an MD from Tel Aviv University and an MPA from Harvard University.
Sigal Kremer-Tal, MD
VP clinical and regulatory
Dr. Sigal Kremer-Tal is a physician entrepreneur with a track record in early-stage development. She is a Co-founder of Spirify Pharma, developing new generation drugs for depression and pain. Sigal also serves as Chief Medical Officer at T-syte, a fresh accelerator focusing on Digital Health. She is also an 8400 fellow in cohort #3.
Sigal is a Co-founder at Cordio Medical, a digital-health voice analysis start-up. She has served as CEO of Xerem Medical, Chief Medical Officer at RAD BioMed, and a Management Committee Member volunteer at the BioExecutive Forum. Dr. Kremer-Tal has engaged in clinical research at Novartis USA and cancer genetics at Mount Sinai School of Medicine, New York. She earned her medical degree from the Hebrew University.
Einav Ratzon Ashkenazi
Einav is a senior project manager in the MIGAL institute, specialized in protein science and drugs discovery. Ms. Ashkenazi is holding BSc and MSc in Biotechnology.